How to Get Finasteride in Delaware

What Finasteride Is and Why the Dose Matters

Finasteride is a 5-alpha-reductase type II inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT). The FDA approved the 1 mg tablet (brand name Propecia) for androgenetic alopecia (AGA) in men in 1997, and the 5 mg tablet (brand name Proscar) for benign prostatic hyperplasia (BPH) in 1992. These are not interchangeable by indication in clinical practice, and Delaware prescribers write them on two separate NDC codes.

DHT drives miniaturization of hair follicles in men with AGA and also stimulates prostate growth. Finasteride at 1 mg reduces serum DHT by approximately 70%, while 5 mg reduces it by roughly 70 to 75%, a difference that is clinically modest but that guides dosing selection [1]. The FDA label explicitly restricts finasteride use to adult males; the drug is contraindicated in women of childbearing potential because of teratogenic risk to a male fetus [2].

Kaufman et al. (J Am Acad Dermatol, 1998, N=1,553) demonstrated that 48% of men taking finasteride 1 mg daily maintained or increased visible hair count at 24 months, compared with 7% on placebo [3]. Hair loss progression resumed within 12 months of stopping the drug in most participants in that trial, which means Delaware patients starting finasteride for AGA are typically committing to long-term, continuous therapy.

The distinction between indications matters for insurance. Delaware Medicaid covers finasteride 5 mg for BPH with prior authorization (PA), and may cover 1 mg for AGA with PA depending on the specific managed-care plan. Cash-pay generics cost under $15 per month at many Delaware chain pharmacies, so some patients skip the PA process entirely for the AGA indication.

Delaware Prescribing Law and Who Can Write the Prescription

Any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) who holds an active Delaware controlled-substance registration and a valid DEA number may prescribe finasteride in the state. Finasteride is not a controlled substance, so the DEA number requirement applies only if a prescriber is writing scheduled drugs alongside it; for finasteride alone, a standard Delaware medical license is sufficient.

Delaware follows the Interstate Medical Licensure Compact (IMLC), meaning physicians licensed in other compact states may obtain expedited Delaware licensure, which has expanded the pool of telehealth providers who can legally prescribe to Delaware addresses [4]. Delaware also enacted telehealth-specific legislation under Title 24 of the Delaware Code, confirming that a prescription issued after a synchronous video visit meets the same legal standard as one issued in person, provided a valid prescriber-patient relationship is established [5].

Nurse practitioners in Delaware have full practice authority under 24 Del. C. § 1902, meaning they do not require a physician co-signature to prescribe finasteride. PAs prescribe under a supervision agreement but may independently select and authorize finasteride without a physician countersigning every order. Patients should verify that any telehealth platform they use employs providers with active Delaware licenses before completing an intake form.

How to Get a Finasteride Prescription via Telehealth in Delaware

Telehealth is the fastest route. Confirm the provider holds a Delaware license.

Most Delaware-accessible telehealth platforms follow a three-step process: asynchronous intake questionnaire, optional synchronous video visit, then prescription transmission to the patient's preferred pharmacy. The asynchronous path (photo-based assessment for AGA) can result in a prescription in under two hours. Synchronous video visits for BPH evaluation, which require a more detailed urological history, typically run 15 to 30 minutes and end with same-day prescribing if the clinician determines it is appropriate.

The American Urological Association (AUA) 2023 guideline on surgical and medical management of BPH states: "5-alpha-reductase inhibitors are recommended for men with LUTS secondary to BPH who have an enlarged prostate (greater than 30 mL or PSA greater than 1.5 ng/mL) to reduce the risk of acute urinary retention and the need for surgical intervention" [6]. A Delaware telehealth provider evaluating a BPH patient may order a PSA through a local Quest or LabCorp patient service center before finalizing the prescription, adding one to three days to the process.

For AGA, most telehealth clinicians rely on patient-reported history and standardized photos (Norwood-Hamilton scale classification) rather than bloodwork. Lab draws before finasteride for hair loss are not required by the FDA label [2], though some providers order a baseline PSA and testosterone panel to establish a reference point for future monitoring.

The HealthRX clinical team uses the following tiered intake protocol for Delaware finasteride patients:

• Tier 1 (AGA, age <45, no urinary symptoms): Asynchronous photo intake, no required labs, prescription issued within 24 hours if the clinical picture is consistent with AGA.
• Tier 2 (AGA, age 45 to 60, or PSA previously elevated): Synchronous video visit required, baseline PSA ordered before prescribing 1 mg; prescribing decision within 48 hours of lab result.
• Tier 3 (BPH or LUTS, any age): Synchronous video, AUA Symptom Score documented, PSA required, prostate volume estimate requested if prior imaging is available; 5 mg dosing finalized within 72 hours.

This tiered model aligns with the 2023 AUA BPH guideline and the FDA-approved labeling, which recommends PSA monitoring in men on 5 mg finasteride because the drug reduces PSA values by approximately 50% after 6 months, potentially masking prostate cancer signals [2].

In-Person Prescribers in Delaware

Delaware has three main medical centers with urology and dermatology departments that routinely manage finasteride patients: ChristianaCare (Newark and Wilmington), Beebe Healthcare (Lewes), and Bayhealth Medical Center (Dover). Primary care physicians at federally qualified health centers (FQHCs) across the state also prescribe finasteride for both indications without the need for a specialist referral.

Men with BPH in Sussex County can access outpatient urology at Beebe Medical Group, where providers routinely follow the AUA 2023 guideline flowchart for alpha-blocker plus 5-ARI combination therapy in men with prostate volumes above 30 mL [6]. Combination therapy (finasteride 5 mg plus tamsulosin 0.4 mg) was examined in the MTOPS trial (N=3,047), which found that combination treatment reduced the 4-year risk of overall clinical progression by 66% compared with placebo, versus 34% for finasteride monotherapy [7]. Delaware urologists at academic centers will typically reference MTOPS when deciding whether a patient needs combination versus monotherapy.

For AGA, Delaware-based dermatologists at ChristianaCare's Department of Dermatology and at private practices in Wilmington prescribe finasteride 1 mg. Some also offer off-label topical finasteride 0.25% solutions compounded by Delaware 503A pharmacies, which may reduce systemic DHT suppression and associated sexual side-effect risk, though head-to-head randomized data in large US populations remain limited [8].

Pharmacies and Dispensing Options in Delaware

Standard retail pharmacies, licensed 503A compounding pharmacies, and mail-order operations all dispense finasteride legally in Delaware.

Retail chain pharmacies. CVS, Walgreens, Rite Aid, and ShopRite locations across Delaware fill generic finasteride prescriptions. GoodRx pricing at Delaware zip codes shows finasteride 1 mg (30 tablets) for approximately $10 to $18, and finasteride 5 mg (30 tablets) for approximately $15 to $28, depending on the specific pharmacy and coupon applied. Delaware participates in the federal 340B drug pricing program for eligible health centers, so patients seen at FQHCs may access even lower pricing.

503A compounding pharmacies. A 503A pharmacy compounds drugs for individual patients based on a valid prescription. Delaware-licensed 503A pharmacies may compound finasteride in non-commercially-available forms, including topical solutions and customized capsule strengths, provided the preparation does not copy a commercially available product without clinical justification. The FDA outlines 503A requirements under Section 503A of the Federal Food, Drug, and Cosmetic Act [9]. Delaware pharmacies operating under 503A are licensed by the Delaware Board of Pharmacy and must comply with USP Chapter 795 standards for non-sterile compounding [10]. Patients requesting compounded finasteride should confirm their pharmacy holds an active Delaware Board of Pharmacy license.

Mail-order and specialty telehealth pharmacies. Several national mail-order pharmacies ship to Delaware addresses under their state licensure. Patients using out-of-state telehealth platforms should confirm the prescribing provider holds a Delaware license and that the dispensing pharmacy is licensed to ship into Delaware. The Delaware Board of Pharmacy maintains a public online license verification tool.

Transferring an Existing Finasteride Prescription to Delaware

Patients relocating to Delaware can transfer a non-expired finasteride prescription from an out-of-state pharmacy to any licensed Delaware retail pharmacy. Because finasteride is not a controlled substance, state transfer restrictions that apply to Schedule II through V drugs do not apply here. A Delaware pharmacist may accept a verbal, faxed, or electronic transfer from the original dispensing pharmacy.

Patients whose prescription was issued by a provider licensed only in another state face a separate issue: the prescription remains technically valid for dispensing at a Delaware pharmacy (since finasteride is not Schedule II), but refills may be declined if the prescribing provider cannot legally prescribe to a Delaware patient going forward. Establishing care with a Delaware-licensed provider promptly after relocating avoids a gap in therapy. Hair loss studies consistently show that cessation of finasteride leads to a return to pre-treatment hair loss rates within 9 to 12 months [3], so gaps longer than a few weeks are worth avoiding from a clinical standpoint.

If a patient's finasteride was covered under an out-of-state insurance plan, Delaware insurance or Medicaid enrollment will require a new PA submission. The PA process for Delaware Medicaid typically requires documentation of diagnosis (ICD-10 code L64.0 for AGA or N40.1 for BPH with LUTS), a prescriber attestation, and, for BPH, a PSA result and AUA Symptom Score.

Delaware Medicaid, Insurance, and Prior Authorization

Delaware Medicaid covers finasteride 5 mg for BPH under the Diamond State Health Plan (DSHP), administered by Centene-affiliated plans, with a PA requirement. The PA submission must include the ICD-10 diagnosis code, documentation of prostate size or PSA elevation confirming symptomatic BPH, and a prescriber note explaining why the drug is medically necessary. Approval typically takes 3 to 5 business days.

Coverage for finasteride 1 mg for AGA under Delaware Medicaid is less consistent. The AGA indication is considered cosmetic by some managed-care reviewers, and PA denial rates for that indication are higher than for BPH. Patients appealing a denial can reference the Kaufman et al. 1998 trial data showing statistically significant hair count improvement (P<0.001) at 24 months to support medical necessity arguments [3].

Private insurance in Delaware, including plans sold through the ACA marketplace (healthcare.gov), varies widely. Several major carriers (Aetna, Highmark Delaware, Cigna) cover generic finasteride 5 mg for BPH at Tier 1 or Tier 2 cost-sharing with a PA. For finasteride 1 mg, coverage is plan-specific; patients should call the member services number on their insurance card before filling to confirm benefit status.

The American Academy of Dermatology (AAD) guideline on androgenetic alopecia states: "Finasteride 1 mg/day is recommended for treatment of male pattern hair loss; it has been shown to slow hair loss and increase hair growth in clinical studies" [11]. This language from a named specialty society guideline supports PA appeals for insurance plans that require evidence-based justification.

Monitoring, Follow-Up, and Long-Term Management in Delaware

After starting finasteride, the standard monitoring schedule differs by indication.

For AGA (1 mg), most guidelines suggest a clinical reassessment at 12 months to determine whether hair count has stabilized or improved, since visible benefit is rarely apparent before 6 months [3]. Sexual side effects, including decreased libido, ejaculatory dysfunction, and erectile dysfunction, occur in approximately 3.8% of men in controlled trials [2]. Patients experiencing persistent sexual symptoms lasting more than 3 months after stopping finasteride should be evaluated for post-finasteride syndrome, a condition recognized in FDA label updates in 2012 [2]. Delaware clinicians can refer affected patients to ChristianaCare's urology or endocrinology departments for further hormonal evaluation.

For BPH (5 mg), PSA monitoring is clinically significant. Because finasteride reduces PSA by roughly 50% after 6 months of continuous use, a PSA value measured during finasteride therapy must be doubled to approximate the actual PSA level for prostate cancer screening purposes [2]. The Prostate Cancer Prevention Trial (N=18,882) found that finasteride reduced prostate cancer incidence by 24.8% overall but was associated with a higher proportion of high-grade tumors in the finasteride group compared with placebo, a finding that remains under active discussion in urology [12]. Delaware urologists generally follow the AUA's recommendation to continue PSA monitoring, with values interpreted using the doubling convention, every 12 months in men on finasteride 5 mg [6].

Men using finasteride for BPH who do not see symptom improvement on AUA Symptom Score reassessment at 6 to 12 months may need evaluation for other etiologies, including bladder dysfunction or urethral stricture, at a Delaware urology clinic.

What to Expect: Timeline From Inquiry to First Dose

For most Delaware patients pursuing the telehealth route for AGA, the sequence looks like this: complete intake (day 1), receive prescriber decision (day 1 to 2), pharmacy processes prescription (day 2 to 3), and pick up or receive mail delivery (day 3 to 5). That is a worst-case estimate; same-day prescribing and next-day pharmacy pickup is possible through major chains.

For BPH patients requiring labs, add 2 to 4 days for PSA results before the prescriber finalizes the 5 mg dose.

The 2022 American Hair Loss Association position statement on male pattern baldness notes that early intervention produces better outcomes, because finasteride halts further loss more effectively than it reverses established miniaturization [13]. Starting sooner rather than delaying for weeks of research is therefore consistent with published clinical guidance.

Delaware residents experiencing urinary retention, hematuria, or severe LUTS should be evaluated in person before starting finasteride, since those presentations may require imaging or cystoscopy to rule out conditions finasteride does not treat.